Overview
Kisunla targets amyloid plaque and may be stopped once amyloid clearance is achieved on imaging.
Who it is for
- Biomarker-confirmed early symptomatic Alzheimer's disease
- Able to complete infusions and MRI surveillance
- Risk profile reviewed, including APOE4 status and anticoagulant use
What is involved
- Infusions on a set schedule
- Periodic amyloid PET to assess clearance
- Serial MRI to monitor for ARIA
Risks
- ARIA-E (swelling) and ARIA-H (microbleeds)
- Infusion-related reactions
- Rare serious events, including brain hemorrhage
Related resources
Medically reviewed. Last reviewed August 2026. This page is educational information, not individualized medical advice.